Article
Oncology
Xunxi Lu, Mengting He, Luoting Yu, Zongchao Gou
Summary: This cohort study found that receiving surgical axillary staging was associated with better survival for patients with ipsilateral breast tumor recurrence, and repeat sentinel lymph node biopsy had a similar long-term survival outcome as axillary lymph node dissection. Therefore, repeat sentinel lymph node biopsy may be considered for surgical axillary staging in patients with ipsilateral breast tumor recurrence after lumpectomy and initial sentinel lymph node biopsy.
Article
Surgery
Y. Andersson, L. Bergkvist, J. Frisell, J. de Boniface
Summary: The SENOMIC trial found that omitting axillary lymph node dissection in patients with breast cancer and sentinel node micrometastases had excellent 3-year event-free survival rates. However, patients who underwent mastectomy had worse tumor characteristics and higher risk of recurrence, especially without adjuvant radiotherapy. Long-term follow-up and enrollment of mastectomy patients are crucial.
BRITISH JOURNAL OF SURGERY
(2021)
Article
Oncology
Peiyong Li, Ciqiu Yang, Junsheng Zhang, Yitian Chen, Xiaoqi Zhang, Minting Liang, Na Huang, Yilin Chen, Kun Wang
Summary: Sentinel lymph node biopsy can provide survival results equivalent to axillary lymph node dissection for patients with cN0 and T1-2 breast cancer; however, whether it can be performed on patients with T3-4c breast cancer is still controversial.
Article
Oncology
Gilles Houvenaeghel, Monique Cohen, Pedro Raro, Jeremy De Troyer, Pierre Gimbergues, Christine Tunon de Lara, Vivien Ceccato, Veronique Vaini-Cowen, Christelle Faure-Virelizier, Frederic Marchal, Tristan Gauthier, Eva Jouve, Pierrick Theret, Claudia Regis, Philippe Gabelle, Julia Pernaut, Francesco Del Piano, Gauthier D'Halluin, Stephane Lantheaume, Emile Darai, Bassoodeo Beedassy, Caroline Dhainaut-Speyer, Xavier Martin, Sophie Girard, Richard Villet, Emilie Monrigal, Theophile Hoyek, Jean-Francois Le Brun, Pierre-Emmanuel Colombo, Agnes Tallet, Jean-Marie Boher
Summary: The study analyzed the treatment and pathological results of patients included in the SERC trial, a multicenter randomized non-inferiority phase-3 trial comparing completion axillary lymph node dissection (cALND) with sentinel lymph node biopsy alone in breast cancer patients. Patients with one or two involved sentinel nodes by micro- or macro-metastases may not require cALND, but further research is needed for those with more than two involved nodes.
Article
Oncology
Jing Si, Rong Guo, Huan Pan, Xiang Lu, Zhiqin Guo, Chao Han, Li Xue, Dan Xing, Wanxin Wu, Caiping Chen
Summary: The aim of this study was to determine whether breast cancer patients with mastectomy and false-negative frozen section in sentinel lymph node biopsy (SLNB) could forgo axillary lymph node dissection (ALND). The study found that SLNB and axillary radiation therapy could effectively replace ALND in selected patients who met specific criteria.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ji Young You, Eun Sook Lee, Siew Kuan Lim, Youngmee Kwon, So-Youn Jung
Summary: According to the study, performing sentinel lymph node biopsy (SLNB) without axillary lymph node dissection (ALND) may be a reasonable treatment option for patients with positive lymph nodes after breast cancer surgery. There was no significant difference in the loco-regional recurrence rates between SLNB with ALND and SLNB alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ian Campbell, Neil Wetzig, Owen Ung, David Espinoza, Gelareh Farshid, John Collins, James Kollias, Val Gebski, Rebecca Mister, R. John Simes, Martin R. Stockler, Grantley Gill
Summary: For early breast cancer patients who are clinically node-negative, sentinel node-based management (SNBM) is the international standard of care. In the SNAC1 study, we report the rates of axillary recurrence, overall survival, and breast cancer-specific survival at 10 years.
Article
Oncology
Zhao Bi, Jia-Jian Chen, Peng-Chen Liu, Peng Chen, Wei-Li Wang, Yan-Bing Liu, Chun-Jian Wang, Peng-Fei Qiu, Qing Lv, Jiong Wu, Yong-Sheng Wang
Summary: This study developed a predictive model based on a multi-center retrospective database to accurately predict whether HR+/HER2- patients can undergo genomic tests. Through multivariate logistic regression analysis, imaging abnormal nodes, the number of positive SLNs, the number of negative SLNs, pathological tumor stage, and lympho-vascular invasion were identified as independent predictors for patients having <= 3 total metastatic ALNs.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Qiufan Zheng, Hanjia Luo, Wen Xia, Qianyi Lu, Kuikui Jiang, Ruoxi Hong, Fei Xu, Shusen Wang
Summary: This study found significant differences in overall survival and breast cancer-specific survival between SLNB and ALND, with SLNB showing a slight survival advantage.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Toralf Reimer
Summary: The local treatment of axilla in early breast cancer patients without clinically evident lymph node metastases is a subject of debate. Various prospective randomized surgical trials are currently being conducted to evaluate the safety of omitting sentinel lymph node biopsy in upfront breast-conserving surgery and neoadjuvant setting. These trials aim to determine whether it is possible to make therapeutic decisions without pathologic evaluation of nodal status. Additionally, ongoing trials are investigating the possibility of de-escalating surgery based on the response to neoadjuvant systemic therapy.
Review
Surgery
Nur Amalina Che Bakri, Richard M. Kwasnicki, Naairah Khan, Omar Ghandour, Alice Lee, Yasmin Grant, Aleksander Dawidziuk, Ara Darzi, Hutan Ashrafian, Daniel R. Leff
Summary: This study evaluated the impact of axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SLNB) on upper limb morbidity in breast cancer patients. The results showed that ALND patients had higher prevalence of lymphedema, pain, reduced strength, and range of motion compared with SLNB patients. These findings support the continued de-escalation of axillary surgery.
Article
Oncology
R. Haarsma, A. A. van Loevezijn, M. L. Donswijk, A. N. Scholten, M. T. F. D. Vrancken Peeters, F. H. van Duijnhoven
Summary: The added value of repeat sentinel lymph node biopsy (rSLNB) in clinically node-negative (cN0) patients with ipsilateral breast tumor recurrence (IBTR) who underwent optimal clinical staging with FDG-PET/CT was assessed. The study found that the incidence of a tumor-positive rSLNB in patients with a negative FDG-PET/CT is low and does not change survival. Therefore, rSLNB can be omitted in these cN0 patients.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Maria Cristina Leonardi, Camilla Arrobbio, Sara Gandini, Stefania Volpe, Francesca Colombo, Eliana La Rocca, Viviana Galimberti, Sabrina Kahler-Ribeiro-Fontana, Cristiana Fodor, Samantha Dicuonzo, Damaris Patricia Rojas, Maria Alessia Zerella, Anna Morra, Emilia Montagna, Marco Colleoni, Giovanni Mazzarol, Laura Lavinia Travaini, Mattia Zaffaroni, Paolo Veronesi, Roberto Orecchia, Barbara Alicja Jereczek-Fossa
Summary: This study aimed to evaluate the rate of positive non-sentinel lymph nodes in breast cancer patients after neoadjuvant systemic therapy following positive sentinel lymph node biopsy. Positive non-SLNs were found in 62.3% of cases and were significantly associated with older age, clinically positive lymph nodes, SLN extracapsular extension, and a higher ratio of positive SLNs/total SLNs. ECE and higher nodal ratio were independent predictors of III axillary level positivity.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Rachel E. E. Sargent, Emily Siegel, Fumito Ito, Katherine Kramme, Elizabeth Kraft, Vera Hendrix, Azadeh A. A. Carr, Maria E. E. Nelson, Shelly X. X. Bian, Priya Jayachandran, Stephen F. F. Sener
Summary: This retrospective study aimed to determine the rate of axillary lymph node recurrence in patients with pretreatment biopsy-proven axillary metastases and who were clinically node-negative after neoadjuvant chemotherapy (NAC) using wire-directed (WD) sentinel lymph node dissection (SLND). The results showed that axillary node recurrence was very rare after WD SLND for patients who had pretreatment biopsy-proven node metastases and were ypN0 after NAC. These patients would not likely benefit from additional completion ALND to SLND.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Tibor A. Zwimpfer, Fabienne D. Schwab, Daniel Steffens, Felix Kaul, Noemi Schmidt, James Geiger, Franziska Geissler, Viola Heinzelmann-Schwarz, Walter P. Weber, Christian Kurzeder
Summary: In this case report, a 37-year-old patient with CALNM in a ipsilateral relapse of breast cancer is described. The use of delayed lymphoscintigraphy and the sentinel procedure aided in accurate staging and treatment. The findings suggest that CALNM without evidence of systemic metastasis should be considered a regional event in recurrent breast cancer, allowing for a curative approach.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
